首页> 外文期刊>Cancer science. >miR‐25‐3p reverses epithelial‐mesenchymal transition via targeting Sema4C in cisplatin‐resistance cervical cancer cells
【24h】

miR‐25‐3p reverses epithelial‐mesenchymal transition via targeting Sema4C in cisplatin‐resistance cervical cancer cells

机译:miR-25-3p通过靶向Sema4C在顺铂耐药宫颈癌细胞中逆转上皮-间质转化

获取原文
           

摘要

Acquisition of epithelial-mesenchymal transition (EMT) has recently been proposed as an important contributor of drug resistance in cervical cancer cells. However, the underlying mechanisms are still unclear. MicroRNAs play a crucial role in regulating EMT. The aim of this study was to explore the potential role of miR-25-3p in regulating EMT in cisplatin-resistant (CR) cervical cancer cells. To this end, we established stable CR cervical cancer cells, HeLa-CR and CaSki-CR, and investigated the function of miR-25-3p in regulating EMT. It is found that CR cervical cancer cells possessed more EMT characteristics and demonstrated higher migratory abilities and invasiveness. miR-25-3p downregulation was also seen in HeLa-CR and CaSki-CR cells. Of note, ectopic expression of miR-25-3p reversed the EMT phenotype and sensitized CR cells to cisplatin via targeting Sema4C. Furthermore, stable overexpression of miR-25-3p in HeLa-CR cells suppressed tumor growth in mice, downregulated Sema4C and Snail, and upregulated E-cadherin compared with the control group. These results suggest that miR-25-3p is an important regulator of cervical cancer EMT and chemoresistance. Thus, upregulation of miR-25-3p could be a novel approach to treat cervical cancers that are resistant to chemotherapy.
机译:最近已经提出,上皮-间质转化(EMT)的获得是宫颈癌细胞中耐药性的重要贡献者。但是,其潜在机制仍不清楚。 MicroRNA在调节EMT中起着至关重要的作用。这项研究的目的是探讨miR-25-3p在调节顺铂耐药(CR)宫颈癌细胞EMT中的潜在作用。为此,我们建立了稳定的CR宫颈癌细胞HeLa-CR和CaSki-CR,并研究了miR-25-3p在调节EMT中的功能。发现CR宫颈癌细胞具有更多的EMT特征,并表现出更高的迁移能力和侵袭性。在HeLa-CR和CaSki-CR细胞中也发现miR-25-3p下调。值得注意的是,miR-25-3p的异位表达通过靶向Sema4C逆转了EMT表型,并使CR细胞对顺铂敏感。此外,与对照组相比,稳定的miR-25-3p在HeLa-CR细胞中的过度表达抑制了小鼠的肿瘤生长,下调了Sema4C和Snail,并上调了E-钙粘蛋白。这些结果表明,miR-25-3p是宫颈癌EMT和化学抗性的重要调节剂。因此,miR-25-3p的上调可能是治疗对化疗耐药的宫颈癌的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号